tiprankstipranks
Advertisement
Advertisement

TYRA Stock Latest News

Tyra Biosciences Advances First‑in‑Human TYRA‑430 Trial in FGFR‑Driven Liver and Solid Tumors
Company AnnouncementsTyra Biosciences Advances First‑in‑Human TYRA‑430 Trial in FGFR‑Driven Liver and Solid Tumors
5d ago
TYRA
Tyra Biosciences Advances TYRA-200 Into First-in-Human FGFR2 Cancer Trial
PremiumCompany Announcements
Tyra Biosciences Advances TYRA-200 Into First-in-Human FGFR2 Cancer Trial
5d ago
TYRA
Analyst Maintains Buy on Tyra Biosciences, Reiterates $50 Price Target on NMIBC Opportunity
PremiumRatings
Analyst Maintains Buy on Tyra Biosciences, Reiterates $50 Price Target on NMIBC Opportunity
12d ago
TYRA
Tyra Biosciences: Buy Rating Reaffirmed, $50 Price Target Maintained on Strong Dabogratinib Potential
PremiumRatings
Tyra Biosciences: Buy Rating Reaffirmed, $50 Price Target Maintained on Strong Dabogratinib Potential
19d ago
TYRA
Blair adds American Express, Oracle to Conviction List in monthly update
PremiumThe Fly
Blair adds American Express, Oracle to Conviction List in monthly update
1M ago
P
CW
Tyra Biosciences assumed with an Outperform at Oppenheimer
PremiumThe FlyTyra Biosciences assumed with an Outperform at Oppenheimer
2M ago
TYRA
Tyra Biosciences initiated with a Buy at JonesResearch
Premium
The Fly
Tyra Biosciences initiated with a Buy at JonesResearch
2M ago
TYRA
Tyra Biosciences price target raised to $42 from $37 at BofA
Premium
The Fly
Tyra Biosciences price target raised to $42 from $37 at BofA
2M ago
TYRA
Analyst Initiates Buy on Tyra Biosciences, Citing De-Risked Dabogratinib Program and Attractive Entry Ahead of Key Bladder Cancer Data
PremiumRatings
Analyst Initiates Buy on Tyra Biosciences, Citing De-Risked Dabogratinib Program and Attractive Entry Ahead of Key Bladder Cancer Data
2M ago
TYRA
Tyra Biosciences Shareholders Reelect Directors and Ratify Auditor
PremiumCompany Announcements
Tyra Biosciences Shareholders Reelect Directors and Ratify Auditor
2M ago
8K
TYRA
Tyra Biosciences Rated Buy on Anticipation of Interim SURF302 Dabogratinib Data in FGFR3‑Driven NMIBC
PremiumRatings
Tyra Biosciences Rated Buy on Anticipation of Interim SURF302 Dabogratinib Data in FGFR3‑Driven NMIBC
2M ago
TYRA
Tyra Biosciences initiated with a Peer Perform at Wolfe Research
PremiumThe Fly
Tyra Biosciences initiated with a Peer Perform at Wolfe Research
3M ago
TYRA
Tyra Biosciences reports Q1 EPS (64c), consensus (59c)
PremiumThe FlyTyra Biosciences reports Q1 EPS (64c), consensus (59c)
3M ago
TYRA
Analyst Reiterates Buy on Tyra as Dabogratinib Catalysts Approach; $50 Price Target Maintained
Premium
Ratings
Analyst Reiterates Buy on Tyra as Dabogratinib Catalysts Approach; $50 Price Target Maintained
3M ago
TYRA
Buy Rating on Tyra Biosciences Backed by Dabogratinib’s Potential to Redefine Intermediate-Risk Bladder Cancer Treatment Ahead of Key Phase II SURF302 Data
Premium
Ratings
Buy Rating on Tyra Biosciences Backed by Dabogratinib’s Potential to Redefine Intermediate-Risk Bladder Cancer Treatment Ahead of Key Phase II SURF302 Data
3M ago
TYRA
Short Report: Lyft short interest at record high
PremiumThe Fly
Short Report: Lyft short interest at record high
3M ago
CAR
ARRY
Dabogratinib’s Differentiated FGFR3 Profile and SURF302 Readout Position Tyra for Upside in Intermediate‑Risk NMIBC
PremiumRatings
Dabogratinib’s Differentiated FGFR3 Profile and SURF302 Readout Position Tyra for Upside in Intermediate‑Risk NMIBC
3M ago
TYRA
Tyra Bioscience Expands Board, Appoints New Independent Director
PremiumCompany Announcements
Tyra Bioscience Expands Board, Appoints New Independent Director
4M ago
8K
TYRA
Tyra Biosciences Advances Dabogratinib Trial in Niche Urothelial Cancer: What Investors Should Watch
PremiumCompany Announcements
Tyra Biosciences Advances Dabogratinib Trial in Niche Urothelial Cancer: What Investors Should Watch
4M ago
TYRA
Tyra Biosciences initiated with a Buy at Guggenheim
PremiumThe FlyTyra Biosciences initiated with a Buy at Guggenheim
4M ago
TYRA
Tyra Biosciences initiated with a Buy at Guggenheim
Premium
The Fly
Tyra Biosciences initiated with a Buy at Guggenheim
4M ago
TYRA
Canaccord starts Tyra Biosciences at Buy into 2026 data readouts
Premium
The Fly
Canaccord starts Tyra Biosciences at Buy into 2026 data readouts
4M ago
TYRA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >